At least two clinics have said that the take-up has been slow for recently approved COVID-19 medication. They said that not many patients are eligible for the antiviral drug known as Paxlovid, and among those who are eligible, several have declined. Some patients said that mild symptoms negate the need, while a few have reported side effects. Dale Fisher, Professor of Medicine at the NUS Yong Loo Lin School of Medicine and Chair of the Global Outbreak Alert and Response Network at WHO, shared his thoughts on this.

Subscribe to our channel here: [ Ссылка ]

Subscribe to our news service on Telegram: [ Ссылка ]

Follow us:
CNA: [ Ссылка ]
CNA Lifestyle: [ Ссылка ]
Facebook: [ Ссылка ]
Instagram: [ Ссылка ]
Twitter: [ Ссылка ]

свернуть